TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Change of serum creatinine from baseline
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Change of blood urea nitrogen (BUN) from baseline
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Change of glomerular filtration rate (GFR) from baseline using the Cockcoft-Gault equation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Change of glomerular filtration rate (GFR) from baseline using the MDRD equation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Completion of Tele-Navi LCS
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Rate of cascade genetic testing
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Umbo mobility
Endpoint domain: Physiological/clinical
Endpoint subdomain: Ear outcomes
Primary endpoint: Incus mobility
Endpoint domain: Physiological/clinical
Endpoint subdomain: Ear outcomes
Primary endpoint: 6-month Progression-free survival (PFS) rate
Endpoint domain: Mortality/survival
Primary endpoint: Change in percentage of contribution of coma and spherical aberration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Gingival recession
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Successful breastfeeding
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Severity of ocular and non-ocular adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Mean change in best corrected visual acuity (BCVA) from Baseline
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Median symptomatic score reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of subjects achieving PASI 90 response or higher
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Arterial oxygen pressure / fraction of inspired oxygen (pO2 /FiO2) ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: MTD of CBP-1018
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Recommended Phase 2 dose (RP2D) of CBP-1018
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Success rate of the investigators' overall assessment (IGA) for acne vulgaris
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Detection of neutralizing antibodies
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Dose of oral pancreatic enzymes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Stoppage of diarrhea
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Changes in EuroQol five dimensions questionnaire (EQ-5D-5L) score
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Changes in shortForm 6D (SF-6D) questionnaire score
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Area under the ziltivekimab plasma concentration-time curve
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Degree of rectal mucosal injury
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Change of inhibitory control ability
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change of theta(θ) phase synchronicity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change of theta-gamma phase amplitude coupling(θ-γ PAC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Acute readmissions
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: C. difficile specific antibodies
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Cardiologist satisfaction
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Tumor Distance From Margins
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Body Esteem Scale for Adolescents and Adults - Appearance subscale
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Correlation of FiO2 and ORi value
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Age of CP diagnosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Speech, Spatial & Qualities of Hearing scale (SSQ12)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: FEV1 (Forced Expiratory Volume per second)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: CASA-Q (Cough and Sputum Assessment Questionnaire)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Auscultatory Breath Sound
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Cryoablation completion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Assessment of pain pressure threshold
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Menstrual distress questionnaire (MDQ)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in Dynamic balance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Self reported quality of life
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Change in Self-care behaviour
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: Change in Glycosylated hemoglobin(HbA1c) levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: IBS Severity Score Scale (IBS-SSS)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Mean change in cytokine responses
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Diagnostic accuracy of sonography in radial head fractures
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Occurrence of moderate and severe bleeding events
Endpoint domain: Adverse events/effects
Primary endpoint: Change in pain score at 4 weeks
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in pain score at 6 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: concentration of hepcidin
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: concentration of erythroferone
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: skeletal muscle ultrasound thickness
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: skeletal muscle cross sectional area (cm2)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Implant stability / osseointegration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area under the plasma concentration-time curve (AUC) of LP-128
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Apparent terminal phase half-life (T1/2) of LP-128
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum observed plasma concentration (Cmax) of LP-128
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Adverse events of LP-128
Endpoint domain: Adverse events/effects
Primary endpoint: Change from Baseline in QTc
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Peak plasma concentration of SR419
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time of peak plasma concentration of SR419
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area under the plasma concentration-time curve of SR419
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Hepatic glycogenosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Liver outcomes
Primary endpoint: Blood levels of creatine phosphokinase (CK)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Composite Memory
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Executive Function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Dorsiflexion lunge test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Foot and Ankle outcome score
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: LVEF increase (metric)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: LVEF increase (binary)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in neuropsychological assessment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Number of subjects with treatment emergent adverse events (TEAE)
Endpoint domain: Adverse events/effects
Primary endpoint: Number of subjects with Serious Adverse Events (SAE)
Endpoint domain: Adverse events/effects
Primary endpoint: VExUs score variation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Procedural related pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of patients experiencing Adverse Reactions of Special Interest
Endpoint domain: Adverse events/effects
Primary endpoint: seroconversion rate of hemagglutination inhibition (HI) antibodies
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: geometric mean increase (GMI) of HI antibodies
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: proportion of all adverse reactions/events
Endpoint domain: Adverse events/effects
Primary endpoint: Accuracy of automatic electrode position analysis tools
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: cardiovascular collapse within 30 minutes from the start of the intubation procedure
Endpoint domain: Mortality/survival
Primary endpoint: Clinical cure rate of HSK
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from baseline reactive to non-reactive on COVID 19 RT PCR
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Maximum Observed Serum Concentration (Cmax) of Tezepelumab
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to Achieve Maximum Observed Serum Concentration (Tmax) of Tezepelumab
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area Under the Concentration-Time Curve From Time Zero to The Last Measurable Concentration (AUC0-last) of Tezepelumab
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: fold increase in antibody titer
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Frequency of immunologic responses to purified cancer-testis antigens
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Incidence and severity of SAE
Endpoint domain: Adverse events/effects
Primary endpoint: Change from baseline stress by Perceived Stress Scale (PSS)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change from baseline quality of life by World Health Organization Quality of Life - BREF (WHO-BREF)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Change from baseline mindfulness level by Cognitive and Affective Mindfulness Scale-Revised (CAMS-R)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Proportion of failure of MVA vaccine
Endpoint domain: Adverse events/effects
Primary endpoint: Functional recovery time
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Blood oxygen changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of days at home after surgery
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: Carotid Stenosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Resistive Index
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Intima Media Thickness
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Social Responsiveness Scale
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: The Canadian Occupational Performance Measure
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Short sensory profile
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum Tolerated Dose
Endpoint domain: Physiological/clinical
Primary endpoint: Level of Stress
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Behavioral Health Measure-20 (BHM-20)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Fried's Frailty Phenotype
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clinical Frailty Scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Partial response rate (PRR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Incidence of physician-diagnosed atopic dermatitis
Endpoint domain: Adverse events/effects
Primary endpoint: Changes in the EQ-5D-5L quality of life score
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Changes in the EQ-5D-VAS assessing the patient's general condition
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change in Quality of Life as measured by the emPHasis-10
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Change in meters walked in six-minute walk distance (meters)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of patients with an incidence of death
Endpoint domain: Mortality/survival
Primary endpoint: Anti-wrinkle efficacy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Acceptability of second dose of misoprostol
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change from Baseline stress level
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Percentage of patients with heart rate within the predefined threshold (80-94 bpm) at hour-48
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Percentage of patients dead at 28 days
Endpoint domain: Mortality/survival
Primary endpoint: Success rate of conversion to resection
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Percent Absolute Bioavailability (%F) for TAK-994
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Total Radioactivity (TRA) in Urine (Cum Percent [%] Dose [UR])
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of TRA in Feces (Cum%Dose[FE])
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: primary outcome
Endpoint domain: General outcomes
Primary endpoint: Wound complication/healing
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Effectiveness of antibiotic therapy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Frequency of patients with oncogene addiction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Safety/Tolerability (adverse events)
Endpoint domain: Adverse events/effects
Primary endpoint: Cellular isolevuglandin (isoLG) adducts
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUCt of Irbesartan and Amlodipne
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Cmax of Irbesartan and Amlodipne
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in self-reported quality of Life
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Maximum concentration (Cmax) of alpelisib
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Normative parameters of cutaneous silent period
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Attention-Deficit/Hyperactivity Disorder Rating Scale Version 5 (ADHD-RS-5)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change of FDG uptake of heart
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change of FDG uptake of lungs
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Change of the heart function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change of the lung perfusion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Visual field change
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Death or rehospitalizations
Endpoint domain: Mortality/survival
Primary endpoint: Emergency or urgent care without hospitalization
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Percentage compliance with the CMS 3-hour sepsis bundle criterion (SEP-1)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Fugl-Meyer assessment upper extremity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Chedoke Arm and Hand Inventory
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Keratopathy and Visual Acuity (KVA) scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Post extraction pain at 3 hours
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Post extraction pain at 6 hours
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Post extraction pain at 12 hours
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Post extraction pain at 24 hours
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cutaneous Disease Activity Severity Index (CDASI) activity score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Skin Moisture
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Microbiological profile of ventilator associated pneumonia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Presence of a clinical and/or electrophysiological neuropathy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Nursing Structural Empowerment Scale
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Psychological Empowerment Scale
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: walking motor skills
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Hand Washing Skill Efficacy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to repeat paracentesis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in the rate of agreement on the presence of malnutrition
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in the rate of agreement on the presence of self-reported pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in the rate of agreement on the presence of observed pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in the rate of agreement on the presence of trunk fixation or seating that prevents the resident from rising
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in the rate of agreement on the presence of bedrails
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Complete ablation rate at 12 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Monetary Choice Questionnaire
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Number of received blood components
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Peripartum haemoglobin level drop
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Average agreement in blood pressure measurements
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Return to function (Elbow #1)
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Return to function (Elbow #2)
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Return to function (Elbow #3)
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Return to function (All cohorts)
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Return to Function (Hip)
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning